1.
目前开展的ipilimumab治疗SCLC的Ⅱ期/Ⅲ期临床研究
Summary of phase Ⅱ/Ⅲ clinical trials with ipilimumab in SCLC
| Clinical trial identifier | Phase | Treatment arms | Patient population | Primary endpoint | Status |
| *Paclitaxel/Carboplatin; #Etoposide/Cisplatin; 1Extensive stage small cell lung cancer; △Limited stage small cell lung cancer (SCLC). NSCLC: non-small cell lung cancer. | |||||
|
NCT00527735 (CA184-041) |
Ⅱ | Ipilimumab or placebo+PC* (concurrent) vs ipilimumab or placebo+PC (sequential) vs placebo/PC |
ES-SCLC1 (and NSCLC) | EORTC-QLQ-30 questionnaire |
Completed |
|
NCT01450761 (CA184-156) |
Ⅲ | Ipilimumab+EP# vs EP | ES-SCLC | OS | Ongoing |
|
NCT01331525 (ICE) |
Ⅱ | Ipilimumab+Carboplatin/Etoposide | ES-SCLC | 1-yr PFS | Ongoing |
|
NCT02046733 (STIMULI) |
Ⅱ | Consolidation ipilimumab vs Observation | LS-SCLC△ | OS | Ongoing |